Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Leucovorin Calcium

FDA-approved product (for solution, oral), marketed as Leucovorin Calcium, Leucovorin Calcium Preservative Free, Vykoura and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Leucovorin Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Osteosarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Leucovorin Calcium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Leucovorin Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

    NCT07446465 · start 2026-03-01

    Registered record
    Registry ID
    NCT07446465
    Conditions
    Colorectal Cancer (Locally Advanced or Metastatic); Colorectal Cancer Microsatellite Stable (MSS)
    Interventions
    Serplulimab; Fruquintinib; mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2027-01-31
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer (Locally Advanced or Metastatic); Colorectal Cancer Microsatellite Stable (MSS)
    InterventionSerplulimab; Fruquintinib; mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
    PhasePhase 4
    Registry statusNot yet recruiting

  • Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial

    NCT07106034 · start 2025-08-31

    Registered record
    Registry ID
    NCT07106034
    Conditions
    Advanced Colorectal Cancer
    Interventions
    Ongericimab + Toripalimab + Bevacizumab + FOLFOX; Ongericimab + Toripalimab + Bevacizumab + FOLFIRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-31
    Completion
    2028-07-31
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Colorectal Cancer
    InterventionOngericimab + Toripalimab + Bevacizumab + FOLFOX; Ongericimab + Toripalimab + Bevacizumab + FOLFIRI
    PhasePhase 2
    Registry statusRecruiting

  • Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies

    NCT06993025 · start 2025-05-25

    Registered record
    Registry ID
    NCT06993025
    Conditions
    Biliary Tract Cancer
    Interventions
    Ivonescimab+chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-05-25
    Completion
    2027-04-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Tract Cancer
    InterventionIvonescimab+chemotherapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study

    NCT07542002 · start 2025-03-25

    Registered record
    Registry ID
    NCT07542002
    Conditions
    Pancreatic Cancer
    Interventions
    Irinotecan liposome, 5-fluorouracil/leucovorin, and oxaliplatin, with or without adadelimab.
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-25
    Completion
    2026-05-31
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionIrinotecan liposome, 5-fluorouracil/leucovorin, and oxaliplatin, with or without adadelimab.
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    NCT06750094 · start 2024-12-12

    Registered record
    Registry ID
    NCT06750094
    Conditions
    Colorectal Neoplasms
    Interventions
    Amivantamab; Cetuximab; Bevacizumab; 5-fluorouracil; Leucovorin calcium/Levoleucovorin; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-12-12
    Completion
    2029-04-13
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasms
    InterventionAmivantamab; Cetuximab; Bevacizumab; 5-fluorouracil +2 more
    PhasePhase 3
    Registry statusRecruiting

  • Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer

    NCT06387810 · start 2024-04-17

    Registered record
    Registry ID
    NCT06387810
    Conditions
    Borderline Resectable Pancreatic Cancer
    Interventions
    irinotecan liposome II combined with 5-FU/LV and oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2024-04-17
    Completion
    2026-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBorderline Resectable Pancreatic Cancer
    Interventionirinotecan liposome II combined with 5-FU/LV and oxaliplatin
    PhasePhase 2
    Registry statusUnknown

  • Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

    NCT06099951 · start 2023-11-01

    Registered record
    Registry ID
    NCT06099951
    Conditions
    Colorectal Cancer
    Interventions
    Serplulimab + FOLFOXIRI; Radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2023-11-01
    Completion
    2027-09-01
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionSerplulimab + FOLFOXIRI; Radiation therapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

    NCT05713838 · start 2023-08-28

    Registered record
    Registry ID
    NCT05713838
    Conditions
    Esophagus Adenocarcinoma
    Interventions
    Durvalumab; FLOT; mFOLFOX-6; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-08-28
    Completion
    2028-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophagus Adenocarcinoma
    InterventionDurvalumab; FLOT; mFOLFOX-6; Radiotherapy
    PhasePhase 2
    Registry statusActive not recruiting

  • A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

    NCT05945901 · start 2023-08-14

    Registered record
    Registry ID
    NCT05945901
    Conditions
    Colorectal Cancer
    Interventions
    HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab; HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2023-08-14
    Completion
    2026-12-01
    Enrolment
    669

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionHR070803 plus oxaliplatin, 5-FU/LV, bevacizumab; HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Venetoclax Basket Trial for High Risk Hematologic Malignancies

    NCT05292664 · start 2023-03-29

    Registered record
    Registry ID
    NCT05292664
    Conditions
    Myelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia; Therapy-Related Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; Lymphoblastic Lymphoma, in Relapse; Lymphoblastic Lymphoma, Refractory; Acute Leukemia of Ambiguous Lineage in Relapse; Acute Leukemia of Ambiguous Lineage
    Interventions
    Venetoclax; Azacitidine; Cytarabine; Methotrexate; Hydrocortisone; Leucovorin; Dexamethasone; Vincristine; Doxorubicin; Dexrazoxane; Calaspargase Pegol; Erwinia asparaginase
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-03-29
    Completion
    2030-07-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia +7 more
    InterventionVenetoclax; Azacitidine; Cytarabine; Methotrexate +8 more
    PhasePhase 1
    Registry statusRecruiting

  • Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

    NCT06313801 · start 2023-01-19

    Registered record
    Registry ID
    NCT06313801
    Conditions
    Gastric Cancer
    Interventions
    Docetaxel; Oxaliplatin; Calcium folinate; Fluorouracil; Diagnostic laparoscopy; dPIPAC ( The description of the standard diagnostic laparoscopy procedure and the session of PIPAC (dPIPAC)).
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-01-19
    Completion
    2027-09-01
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    InterventionDocetaxel; Oxaliplatin; Calcium folinate; Fluorouracil +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

    NCT02697838 · start 2016-08-01

    Registered record
    Registry ID
    NCT02697838
    Conditions
    Malignant Neoplasm of Stomach Stage II
    Interventions
    Apatinib; Paclitaxel-based chemotherapeutic regimens
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-08-01
    Completion
    2018-10-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm of Stomach Stage II
    InterventionApatinib; Paclitaxel-based chemotherapeutic regimens
    PhasePhase 2
    Registry statusUnknown

  • Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

    NCT02293109 · start 2015-12-17

    Registered record
    Registry ID
    NCT02293109
    Conditions
    Contiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia
    Interventions
    carfilzomib; cyclophosphamide; vincristine sulfate; doxorubicin hydrochloride; dexamethasone; methotrexate; cytarabine; leucovorin calcium; methylprednisolone; rituximab; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-12-17
    Completion
    2018-01-11
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma +2 more
    Interventioncarfilzomib; cyclophosphamide; vincristine sulfate; doxorubicin hydrochloride +7 more
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours

    NCT02591030 · start 2015-12-15

    Registered record
    Registry ID
    NCT02591030
    Conditions
    Bile Duct Cancer
    Interventions
    GEMCIS; mFolfirinox
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-12-15
    Completion
    2020-01-16
    Enrolment
    191

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBile Duct Cancer
    InterventionGEMCIS; mFolfirinox
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

    NCT02003222 · start 2014-05-19

    Registered record
    Registry ID
    NCT02003222
    Conditions
    Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
    Interventions
    Allogeneic Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy; Cyclophosphamide; Cytarabine; Daunorubicin; Daunorubicin Hydrochloride; Dexamethasone; Etoposide; Leucovorin Calcium; Lumbar Puncture; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Rituximab; Vincristine; Vincristine Sulfate; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2014-05-19
    Completion
    2027-02-25
    Enrolment
    488

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
    InterventionAllogeneic Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration +17 more
    PhasePhase 3
    Registry statusActive not recruiting